Dr. Kabour: Additional Published studies

Kush Patel, Alexandra Lansky, Dean J. Kereiakes, ….Ameer Kabour,..etal. Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Sub study.

Journal of the Society for Cardiovascular Angiography & Interventions1(1):100004

Jan 2022

Santiago Garcia, MD, Payam Dehghani, MD, Cindy Grines, MD, Ameer Kabour, MD, et al on behalf of the Society for Cardiac Angiography and Interventions, the Canadian Association of Interventional Cardiology, and the American College of Cardiology Interventional Council. Initial Findings From the North American COVID-19 Myocardial Infarction Registry.

J Am Coll Cardiol. 2021 Apr 27; 77(16):

P. 1994–2003.

Sharath C. Vipparthy Venkatesh Ravi, Sindhu Avula, .... Ameer Kabour, et al. Meta -Analysis of Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients with Low Surgical Risk.

The American Journal of Cardiology/125(3),

Feb 2020. p. 459 - 468.

Muhammad Shayan Khan, Farhad Sami, Hemindermeet Singh, Waqas Ullah, Ma'en Al-Dabbas, Khalid Hamid, Changal, Tanveer Mir, Zain Ali, Ameer Kabour.

Medical therapy vs early revascularization in diabetics with chronic total occlusions: A meta-analysis and systematic review.

World J Cardiol 2020 Nov 26; 12(11): 559-570.

Kereiakes DJ1, Ellis SG2, Metzger DC3, ........ Kabour A9, Stone GW10; et al. ABSORB III Investigators. Clinical Outcomes Before and After Complete Everolimus-Eluting Bioresorbable Scaffold Resorption: Five-Year Follow-Up From the ABSORB III Trial.

10.1161/CIRCULATIONAHA.119.042584

G. W. Stone, M.D., S. Ellis, M.D.; T. Gori, M.D.; C. Metzger, M.D.; B. Stein, M.D.; M. Erickson, M.D.; Ameer Kabour, M.D. et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.

Lancet 2018 10 25;392(10157):1530-1540.

Epub 2018 Sep 25.

D.J Kereiakas., C. Metzger.; S.G. Ellis.; R.P. Caputo ….A. Kabour.; et al….3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds

Journal of the American College of Cardiology

70(23) · October 2017

Waksman.R.; Piegari G.N.; Kabour. A.; [..] Garcia H.M.G.; Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions with Short DAPT: 9-Month Angiographic and Clinical Follow-up of the Prospective, Multicenter BioFreedom USA Clinical Trial.

Cardiovascular revascularization medicine: including molecular interventions

18(7) · July 2017

GN. Piegari., A. Kabour,. Et al. Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial.

Cardiovasc Revasc Med 2017 Oct - Nov;18(7):

475-481. Epub 2017 Jul 31.

Sajid Ali, Yousuf Kanjwal, Steven R. Bruhl, Mohammed Alo, Mohammed Taleb, Syed S. Ali, Ameer Kabour, and Owais Khawaja. A meta-analysis of antibacterial envelope use in prevention of cardiovascular implantable electronic device infection.

Ther Adv Infect Dis: 2017 May; 4(3)

Owais Khawaja,1,* Hemindermeet Singh,1 Faraz Luni,1 Ameer Kabour,1 Syed S. Ali,1 Mohammed Taleb,1Hafeezuddin Ahmed,1 John Michael Gaziano,2,3,4,5 and Luc Djoussé. Egg Consumption and Incidence of Heart Failure: A Meta-Analysis of Prospective Cohort Studies.

Front Nutr.2017;4:10

Hemindermeet Singh, Ameer Kabour, Abdur Khan, Sonia Ali Malik, Owais Khawaja, Haris Riaz, Wade Lee, Mark Richards, Johan Aasbo, Faraz khan Luni. MORTALITY EFFECT OF ICD IN PRIMARY PREVENTION OF NON ISCHEMIC CARDIOMYOPATHY: A META ANALYSIS OF RANDOMIZED CONTROL TRIALS.

JACC Volume 69, Issue 11,

Supplement, 21 March 2017, Pages 673

Stephen G. Ellis, M.D., Dean J. Kereiakes, M.D., D. Christopher Metzger, M.D., Ronald P. Caputo, M.D., David G. Rizik, M.D., Paul S. Teirstein, M.D., Marc R. Litt, M.D., Annapoorna Kini, M.D., Ameer Kabour, M.D., Steven O. Marx, M.D., Jeffrey J. Popma, M.D., Robert McGreevy, Ph.D., Zhen Zhang, Ph.D., Charles Simonton, M.D., and Gregg W. Stone, M.D., for the ABSORB III Investigators* Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

N Engl J Med 2015; 373:1905-1915 10.1056/NEJ

3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial

J Am Coll Cardiol 2017 Dec 31;70(23):2852-2862.

Epub 2017 Oct 31.

V. Nauffal, MD, T. Schwann, MD, M. B. Yammine, MD, A.M. El-Hage-Sleiman, MD, M. H. El Zein, MD, A. Kabour, MD, M. C. Engoren, MD, R. H. Habib, Phd. “Impact of prior intracoronary stenting on late outcomes of coronary artery bypass surgery in diabetics with triple-vessel disease”.

J.Thorc. Cardiovasc Surg

May 2015. Volume 149, Issue 5, Pages 1302-1309

FK. Luni., SA.MAlik., AR.Khan, H. Riaz., H. Singh., D. Federman., Y. Kanjawal., O. Dasa., S. Khuder., A. Kabour. Risk of Ischemic Heart Disease in Patients with Sjogren’s Syndrome.

Am J Med Sci 2017 10 4;354(4):395-398.

Epub 2017 May 4.

SA. Badour., KR. Dimitrova., Y. Kani., RF. Tranbaugh., MM. Hajjar., A. Kabour., TA. Shwann., A. Alam., RH. Habib. First and second generation DESs reduce diabetes adverse effect on mortality and reintervention in multivessel coronary disease: 9-Year analysis.

Cardiovasc Revasc Med 2017 Jun 6;18(4):265-273.

Epub 2017 Feb 6.

FK. Luni., H. Singh., AR Khan., SA. Malik., O. Khawaja., W. Lee., H Riaz., A. Kabour., M. Richards., J. Aasbo. Mortality Effect of ICD in Primary Prevention of Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.

J Cardiovasc Electrophysiol 2017 May30;28(5):

538-543. Epub 2017 Mar 30.

V. Nauffal., TA. Schwann., MB. Yammine., AKM> El-Hag-Sleiman., MH. Elzein., A. Kabour., M. Engoren., RH. Habib. Impact of prior intracoronary stenting on late outcomes of coronary artery bypass surgery indiabetics with triple-vessel disease.

J Thorac Cardiovasc Surg 2015 May 10;149(5):

1302-9. Epub 2015 Feb 10.

Laila Al-Shaar, Thomas A. Schwann, Ameer Kabour, Robert H. Habib. “Increased late mortality after coronary artery bypass surgery complicated by isolated new-onset atrial fibrillation: a comprehensive propensity-matched analysis.

J. Thorac Cardiovasc Surg 2014, Nov 14;148(5):1868.e2.

Thomas A. Schwann, Robert F. Tranbaugh, Kamellia R. Dimitrova, Milo C. Engoren, Ameer Kabour, Darryl M. Hoffman, Charles M, Geller, Wilson Ko, Robert H. habib. “Time – varying survival benefit of radial artery versus vein grafting: a multiinstitutional analysis.

Ann Thorac Surg 2014, April 17; 97(4): 1328-34

Thomas A. Schwann, Milo Engoren, Mark Bonnell, Christopher Clancy, Samer Khouri, Ameer Kabour, Tahir Jamil, Robert H. Habib. “Mitral valve repair and bioprosthetic replacement without postoperative anticoagulation does not increase the risk of stroke or mortality”.

Eur J Cardiothorac Surg 2013, July 14; 441(1): 24-31

Gregg W. Stone, MD1, Paul S. Teirstein, MD2, Ian T. Meredith, AM, MBBS, PhD3, Robert C. Stoler, MD4, Abram C. Rabinowitz, MD5, Vincent J. Pompili, MD6, Ameer Kabour, MD7, et al. Three Year Results of the PLATINUM Trial Comparing Platinum Chromium PROMUS element and Cobalt Chromium PROMUS/XIENCE V Everolimus-Eluting Stents. I2 Summit 2013.

Dean J. Kereiakes, others.... and Ameer Kabour, et al, “Clinical and Angiographic Outcomes After Treatment of De Novo Coronary Stenosis With a Novel Platinum Chromium Thin-Strut Stent: Primary results of the PERSEUS Trial”

J.Am.Coll.Cardiol. 2010. 56: 264-271

Ameer Kabour, MD, FACC, FSCAI, and E. Dean Nukta, MD, Facp, FACC, FSCAI: “The Mynx® Vascular Closure Device. Adopting extravascular closure technology in the catheterization lab.

Endovascular Today. May, 2009

T. Feldman, T.N. Levin, and A. Kabour. “Percutaneous Transvenous Mitral Commissurotomy Following Carpentier Ring Annuloplasty” .

The J of Invasive Cardiology. 1997; 9: 184.

Kabour,JR. Henegar, JS. Janicki. “ Angiotensin II induced myocyte necrosis : role of the angiotensin II receptors “

J. Cardiovascular Pharma. 1994;26:547.

JS. Janicki, BB. Matsubara, A. Kabour. “ Myocardial collagen and its functional role “ Book-chapter-28 (Interactive phenomena in the cardiac system)

Adv.Exp Med Biol.1993;346:291.

A. Kabour, JR. Henegar, VR. Devineni, JS. Janicki. “ Prevention of angiotensin II induced myocyte necrosis and coronary vascular damage by lisinopril and losartan in the rat “

Cardiovascular Research. 1995;29:543.

JR. Henegar, A. Kabour, JS. Janicki. “ The role of catecholamine in the angiotensin II related myocyte necrosis and vascular damage “

Craiova’s Research. ( in press ).

Kabour,JR. Henegar, JS. Janicki. “ Ability of beta blocker to prevent angiotensin II related myocyte necrosis “

Circulation.1994.90. 4.part 2. 1712

Kabour, VR.Devineni, JR. Henegar, JS. Janicki “ Mechanism of angiotensin II related coronary vascular injury in renovascular hypertension “

Circulation.1993;88.4, part2.I-634.

JS. Janicki, A. Kabour, JR. Henegar. “ Ventricular hypertrophy in normal and high renin experimental hypertension “

Circulation. 1993;88, 4, part2. I-243

Kabour, JR. Henegar, JS. Janicki. “ The ability of low and high dose angiotensin converting enzyme inhibition to prevent angiotensin II related myocyte necrosis “

JACC. 1993;21: 258A

Kabour, JR. Henegar, JS. Janicki.

“ Angiotensin converting enzymes inhibition prevent volume-overload left and right ventricular hypertrophy “

JACC. 1993;21.258A

Kabour,JR. Henegar, JS. Janicki.

“ The effect of chronic versus intermittent elevation of plasma angiotensin II on myocyte necrosis “

FASEB. J.1993;7: A805

Kabour, JR. Henegar, JS, Janicki.

“ Angiotensin II induced myocyte necrosis: role of AT1 receptors “

J.Mol.Cell. Cardiol. 1993;25 (sup III):27

Kabour, JR. Henegar, JS. Janicki.

“ Prevention of myocyte necrosis in renovascular hypertension using the angiotensin converting enzyme inhibition; Lisinopril “

J.Mol. Cell.Cardiol.1993;25 (sup III):228

Abstracts:

S.A. Badour, K.R. Dimitrova, Y. Kanei, R.F. Tranbaugh, M.M. Hajjar, A. Kabour, T.A. Schwann, and R.H. Habib. Drug Eluting Stent Implantation in Multivessel Coronary Artery Disease Reduces the Adverse Effect of Diabetes on Late Outcomes when Compared to Bare Metal Stent .

AHA 2014

KN, Garratt, C. Lambert, A. kabour, M. Stewart, P. Hall, JW. Phillips, K. Winters, T. Christen, K.D. Dawkins, DP. Lee. TAXUS Liberté paclitaxel-eluting stent with aspirin plus prasugrel is associated with low target vessel failure, bleeding and adverse event rates among diabetic patients with “on-label” stent indications

TCT 2013

T. Schwan, A. Kabour.; The independent effects of anemia and transfusion on mortality in coronary artery bypass surgery.

TCT 2013

A.Kabour.JR. Henegar, JS. Janicki. “ Ability of beta blocker to prevent AII related myocyte necrosis

67th Scientific Session. AHA, Nov 1994.

Kabour, GS. Raviprassad, E. Tjahja, GL.Bower. JS.Janicki. “ Myocardial collagen activity during pregnancy in rats”

ACP meeting. Lake of the Ozark. 1/95

Kabour. JR. Henegar, JS. Janicki. “ Mechanism of AII related coronary vascular injury in renovascular hypertension “

66th Scientific session, AHA, Nov 1993

Kabour.JR. Henegar, JS. Janicki. “ Ventricular hypertrophy in normal and high renin experimental hypertension “

66th Scientific Session, AHA, Nov 1993.

Kabour. JS. Janicki “ ACE-Inhibition prevents remote myocyte necrosis secondary to myocardial infarction “ Central Society for Clinical Research.

Chicago. Oct 1993.

Kabour, JR. Henegar, JS. Janicki “ Ability of beta blocker to prevent AII related myocyte necrosis “

Central Society for Clinical Research

Chicago. Oct 1993

Kabour, B. Forum, Z. Turi“ Absence of coronary artery disease in patients undergoing coronary angiography:

use of a retrospectively derived risk index score. “

ACP meeting. Michigan 1992

Kabour, FH. Smith. “ Effect of dietary low NaCl intake on the microvessel number in rat mesentery “

ACP and OHP meeting 1992

Kabour, J. Heinsimer. “ The impact of clinical trial : in the thrombolytic era “

ACP meeting. may.1992

Kabour, B. Bercu.

“Bilateral rapid atrial rhythm treated with cardioversion “

ACP meeting.May. 1992